1Longley BJ, Reguera MJ, Ma Y. Classes of c-kit activating mutations: proposed mechanisms of action and implications for disease classification and therapy [ J ]. Leuk Res, 2001, 25 (7) : 571-576.
2Chan PM, Ilangumaran S, La Rose J, et al. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region [ J ].Mol Cell Biol, 2003, 23 (9) : 3067-3078.
3Hashimoto K, Matsumura I, Tsujimura T, et al. Necessity of tyrosine 719 and phosphatidylinositol 3 '-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation[J]. Blood, 2003, 101(3) : 1094-1102.
4Piao X, Paulson R, van der Geer P, et al. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1 [ J ].Proc Natl Acad Sci USA, 1996, 93(25) : 14665-14669.
5Shivakrupa R, Bemstein A, Watring N, et al. Tidylinositol 3'-kinaseis required for growth of mast cells expressing the kit catalytic domain mutant[J]. Cancer Res, 2003, 63(15) : 4412-4419.
6Chian R, Young S, Danilkovitch-Miagkova A, et al. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-kit mutant[J]. Blood, 2001, 98(5) : 1365-1373.
7Ning ZQ, Li J, McGuinness M, et al. STAT3 activation is required for Asp(816) mutant c-kit induced tumorigenicity [ J ]. Oncogene,2001,20(33 ) : 4528-4536.
9Akin C, Kirshenbaum AS, Semere T, et al. Analysis of the surface expression of and myelomonocytic cells in patients with mastocytosis[J]. Exp Hematol, 2000, 28(2) : 140-147.
10Worobec AS, Semere T, Nagata H, et al. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis [ J ]. Cancer, 1998,83(10) : 2120-2129.
3Koga H,Kokubo T,Akaishi M,et al.Neonatal onset diffuse cutaneous mastocytosis:A case report and review of the literature[J].Pediatr Dermatol,2010,29(7):152.
